Haemostasis in patients with malignant disease: Treatment-related effects;Hamostase bei malignen erkrankungen - Therapieinduzierte einflusse

Tumor Diagnostik und Therapie

Volumn 19, Issue 2, 1998, Pages 25-34

  Bruhn, H D ^a   Zurborn, K H ^a,b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Reha Klinik Ahrenshoop   (Germany)

Author keywords

Therapeutic influence of anticoagulation; Thrombin as mitogen; Thromboembolic events in malignancies; Tumor cell thromboplastins

Indexed keywords

ASPARAGINASE; BLOOD CLOTTING FACTOR 10; CYTOSTATIC AGENT; ESTROGEN; FIBRINOPEPTIDE A; PLASMINOGEN ACTIVATOR; THROMBIN; THROMBOPLASTIN;

ACUTE PHASE RESPONSE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL PROLIFERATION; CYTOSTASIS; DISSEMINATED INTRAVASCULAR CLOTTING; ESTROGEN THERAPY; HEMOSTASIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PATHOPHYSIOLOGY; REVIEW; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM;

EID: 0031856357     PISSN: 0722219X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Ambrus J L, Ambrus C M: Blood Coagulation in Neoplastic Disease. In: Gastpar H (ed): Onkohämostaseologie. Schattauer, Stuttgart, New York 1976; 167 - 193
2. Andoh K, Kubota T, Takada M, Tanaka H, Kobayashi N, Maekawa T: Tissue factor activity in leukemic cells. Special reference to disseminated intravascular coagulation. Cancer; 59(1987) 748 - 754
3. Avvisati G, Ten CateJ W, Böller H R, Mandelli F: Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet i (1989)122 - 124
4. Bennett B, Booth N A, Croll A, Dawson A A: The bleeding disorder in acute promyelocytic leukemia: fibrinolysis due to u-PA rather than defibrination. Br J Haematol 71 (1989) 511 - 515
5. Berger H, Freudenberg N: Todesursachen bei Malignompatienten. Med Welt 34 (1983) 112 - 118
6. Bern M M, Lokich J J, Wallach S R, Bothe A, Benotti P N, Arkin C F, Greco F A, Huberman M, Moore C: Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Int Med 112 (1990) 423 - 428
7. Bick R L: Alterations of Hemostasis Associated with Malignancy: Etiology, Pathophysiology, Diagnosis and Management. Semin Thromb Hemost 5 (1978) 1 - 26
8. Bruhn H D, Zurborn K H: Influence of clotting factors (thrombin, factor XIII) and of fibronectin on the growth of tumor cells and leukemic cells in vitro. Blut 46 (1983) 85 - 88
9. Bruhn H D, Knapp S, Senger H, Werner H, Zurborn K H: Auswirkungen einer Strahlen- oder Zytostatikatherapie auf das Hämostasesystem. In: TilsnerV, Matthias FR (eds) Blutgerinnung und Onkologie. XXXI. Hamburger Symposion über Blutgerinnung. Editiones Roche, Basel, 1988; 171
10. Bruhn H D, Zurborn K H: Veränderungen des Hämostasesystems bei malignen Erkrankungen und deren klinische Bedeutung. In: Spanuth E (ed) Malignome und Hämostase. Springer, Berlin, Heidelberg, New York 1996; 3 - 15
11. Chahinian A P, Propert K J, Ware J H, Zimmer B, Perry M C, Hirsh V, Skarin A, Kopel S, Holland J F, Comis R L: A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 7 (1989) 993 - 1002
12. Clarke-Pearson D L, Synan I S, Creasman W T: Anticoagulation therapy for venous thromboembolism in patients with gynecologic malignancy. AmJ Ostet Gynecol 147 (1983) 369 - 375
13. Cohen J R, Tenenbaum N, Citron M: Greenfield filter as primary therapy for deep venous thrombosis and/or pulmonary embolism in patients with cancer. Surgery 109 (1991) 12 - 15
14. Costantini V, Zacharski L R: Fibrin and Cancer. Thromb Haemost 69 (1993) 406 - 414
15. de Jong E, Knot Ear, Piket D, Iburg A H C, Rijken D C, Veenhof K H N, Dooijewaard G, ten CateJ W: Increased Plasminogen Activator Inhibition Levels in Malignancy. Thromb Haemostas 57 (1987) 771 - 782
16. Donati M B, Falanga A, Consonni R, Alessio M G, Bassan R, Buelli M, Borin L, Catani L, Pogliani E, Guliotta L, Masera G, Barbui T: Cancer procoagulant in acute non lymphoid leukemia: Relationship of enzyme detection to disease activity. Thromb. Haemostas 64 (1990) 11 - 16
17. Duffy MJ, O'Grady P: Plasminogen activator and cancer. Perspectives and commentaries. Eur. J. Cancer Clin. Oncol. 20 (1984) 577 - 582
18. Dvorak H F: Thrombosis and Cancer. Hum. Pathol 18 (1987) 275 - 284
19. Drapkin R L, Gee T S, Dowling M D, Arlin Z, McKenzie S, Kempin S, Clarkson B: Prophylactic Heparin Therapy in Acute Promyelocytic Leukemia. Cancer 41 (1978) 2484 - 2490
20. Edwards R L, Silver J, Rickles F R: Human Tumor Procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis. Thromb. Haemost. 69 (1993) 205 - 213
21. Francis J L: Haemostasis and cancer. Med. Lab. Sci. 46 (1989) 331 - 346
22. Gasic G J, Gasic T B, Galanti N, Johnson T, Murphy S: Platelettumor-cell interactions in mice. Int. J. Cancer 11 (1973) 704 - 718
23. Gasic G J, Gasic T B, Stewart C C: Antimetastatic effects associated with platelet reduction. Proc. Natl. Acad. Sci. USA 61 (1968) 46 - 52
24. Gastpar H: Beeinflussung der Metastasierung durch Hemmung der Thrombozytenaggregation. Beitr. Onkol. 13 (1982) 290 - 306
25. Goerner A: The influence of anticlotting agents on transplantation and growth of tumor tissue. J. Lab. Clin. Med. 16 (1930) 369 - 372
26. Gordon S G: Tumorprokoagulans, Gerinnung und Fibrinolyse bei malignen Erkrankungen. Hämostaseologie 5 (1985) 160-165
27. Gralnick H R, Abrell E: Studies of the Procoagulant and Fibrinolytic Activity of Promyelocytes in Acute Promyelocytic Leukaemia. Brit. J. Haematol. 24 (1973) 89 - 99
28. Guarini A, Gugliotta L, Timoncini C, Chetti L, Catani L, Russo D, Tura S: Procoagulant cellular activity and disseminated intravascular coagulation in acute non-lymphoid leukaemia. Scand. J. Haematol. 34 (1985) 152 - 156
29. Hagedorn A B, Bowie E J W, Elveback L R, Owen C A: Coagulation abnormalities in patients with inoperable lung cancer. Mayo. Clin. Proc. 49 (1974) 649 - 653
30. Hilgard P: Tumorausbreitung und Metastasierung als Indikation für Antikoagulation und Fibrinolysetherapie. In: Gastpar H (ed) Onkohämostaseologie. Schattauer, Stuttgart New York (1976) 107 - 109
31. Honn K V, Cicone B, Skoff A: Prostacyclin: a potent antimetastatic agent. Sience 212 (1981) 1270 - 1272
32. Kutti J: The management of thrombocytosis. Eur J Haematol 44 (1990) 81 - 88
33. Kwaan H C, Keer H N: Fibrinolysis in cancer. Semin. Thromb. Hemost. 16 (1990) 230 - 235
34. Levine M N, Gent M, Hirsh J, Arnold A, Goodyear M D, Hryniuk W, De Pauw S: The Thrombogenic Effect of Anticancer Drug Therapy in Women With Stage II Breast Cancer. N. Engl. J. Med. 318 (1988) 404 - 407
35. Levine M N, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard K I, Steward D, Goodwin P: Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343 (1994) 886 - 889
36. Licciardello J T W, Moake J L, Rudy Ch K, Karp D D, Hong K: Elevated Plasma von Willebrand Factor Levels and Arterial Occlusive Complications Associated with Cisplatin-Based Chemotherapy. Oncology 42 (1985) 296 - 300
37. Lohrmann H P, Adam W, Heymer B, Kubanek B: Microangiopathic hemolytic anemia in metastatic carcinoma. Report of eight cases. Ann. Intern. Med. 79 (1973) 368 - 375
38. Ludwig H: Anticoagulantien beim fortgeschrittenen Carcinom. Gynäkologe 7 (1974) 204 - 212
39. Markus G: The role of haemostasis and fibrinolysis in the metastatic spread of cancer. Semin. Thromb. Haemost. 10 (1984) 61 - 70
40. Moore F D, Osteen R T, Karp D D, Steele G, Wilson R E: Anticoagulants, venous thromboembolism, and the cancer patient. Arch Surg 116 (1981) 405 - 407
41. Nanninga P B, van Teunenbroek A, Veenhof C H N, Büller H R, ten Cate J W: Low prevalence of coagulation and fibrinoloytic activation in patients with primary untreated cancer. Thromb. Haemost. 64 (1990) 361 - 364
42. Nordström M, Lindblad B, Anderson H, Kjellström T: Deep venous thrombosis and occult malignancy: an epidemiological study. Br Med J 308 (1994) 891 - 894
43. Pearlstein E, Salk P L, Yogeeswaran G, Karpatkin S: Correlation between spontaneous metastastic potential platelet aggregating activity of cell surface extracts and cell surface sialylation in 10 metastatic variant derivatives of a rat renal sarcoma cell line. Proc Natl Acad Sci USA 77 (1980) 4336 - 4339
44. Peuscher F W, Cleton F J, Armstrong L, Stoepman-van Dalen E A, van Mourik J A, van Aken W G: Significance of plasma fibrinopeptide A (fpA) in patients with malignancy. J Lab Clin Med 96 (1980) 5 - 14
45. Poller L, McKernan A, Thomson J M, Elstein M, Hirsh P J, Jonbes J B: Fixed mini-dose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. Br Med J 295 (1987) 1309 - 1312
46. Prandoni P, Lensing A W A, Büller H R, Cogo A, Prins M H, Cattelan A M, Cuppini S, Noventa F, Ten Cate J W: Deep-Vein Thrombosis and the Incidence of Subsequent Symptomatic Cancer. N Engl J Med 327 (1992) 1128 - 1133
47. Rasche H, Dietrich M: Hemostatic abnormalities associated with malignant diseases. Europ. J. Cancer 13 (1977) 1053 - 1064
48. Rickles F R, Edwards R L: Activation of Blood Coagulation in Cancer: Trousseau's Syndrome Revisited. Blood 62 (1983) 14 - 31
49. Rickles F R, Levine M, Edwards R L: Hemostatic alterations in cancer patients. Cancer Metast Rev 11 (1992) 237 - 248
50. Sarasin F P, Eckman M H: Management and prevention of thromboembolic events in patients with cancer-related hypercoagulability states: a risky business. J Gen Intern Med 8 (1993) 476 - 486
51. Schafer A I: Bleeding and thrombosis in myeloproliferative disorders. Blood 64 (1984) 1 - 22
52. Schmidt M B: Die Verbreitungswege der Karzinome und die Beziehungen generalisierter Sarkome zu den leukämischen Neubildungen. Fischer, Jena, 1903
53. Schneider W: Bedeutung von Hämostasestörungen für Diagnostik und Therapie von Tumorkrankheiten. Hämostaseologie 8 (1988) 34 - 36
54. Schöndorf T H, Witt I: Protein C in patients under L-asparaginase treatment. In: Witt I (ed) Protein C - Biochemical and Medical Aspects. Walter de Gruyter, Berlin, New York 1985; 125 - 134
55. Südhoff T, Schneider W: Fibrinolytic mechanisms in tumor growth and spreading. Clin Investig 70 (1992) 631 - 635
56. Sun N C, McAffee W M, Hum G J et al: Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Am J Clin Pathol 71 (1979) 71: 10 - 19
57. Sutor A H, Ritter J: Thrombosen bei Kindern mit akuter lymphatischer Leukämie. Hämostaseologie 12 (1992) 107 - 115
58. Tanaka H, Narahara N, Kurabayashi H, Sadaka H, Andoh K, Uchiyama T, Kobayashi N, Maekawa T: Studies on leukemic cell tissue factor. Thromb Res 53 (1989) 535 - 549
59. Terranova T, Chiossone F: II fattore coagulazione nell'attecchimento delle cellule neopiastiche immesse in circolo. Boll Soc Ital Biol Sper28 (1952) 1224 - 1225
60. Trousseau A: Phlegmasia alba dolens. Clinique médicale de l'hotel-dieu de Paris. The New Sydenham Society, London 1865; 3 - 94
61. Wehmeier A, Schneider W: Megakaryocytes and platelets as the main cause for vascular events in chronic myeloproliferative disease. Hämostaseologie 16 (1996) 151 - 163
62. Weiss R B, Tormey D C, Holland J F, Weinberg V E: Venous Thrombosis During Multimodal Treatment of Primary Breast Carcinoma. Cancer Treat Rep 65 (1981 ) 677 - 679
63. Zacharski L R, Henderson W G, Rickles F E et al: Effect of warfarin anticoagulation on survival in carcinoma of lung, colon, head and neck and prostate: final report of VA cooperative study #75. Cancer 53 (1984) 2046 - 2052
64. Zacharski L R, Costanini V, Wojtukiewicz M Z, Memoli V A, Kududryk B J: Anticoagulants as Cancer Therapy. Sem Oncol 17 (1990) 217 - 227
65. Zacharski L R, Donati M B, Rickies F R: Registry of clinical trials of antithrombotic drugs in cancer: second report. Thromb Haemost 70 (1993) 357 - 360
66. Zurborn K-H, Duscha H, Gram J, Bruhn H D: Investigations of coagulation system and fibrinolysis in patients with disseminated adenocarcinomas and non-Hodgkin's lymphomas. Oncology 47 (1990) 376 - 380
67. Zurborn K-H, Gram J, Glander K, Delbrück K, Pelzer H, Löffler H, Bruhn H D: Influence of cytostatic treatment on the coagulation system and fibrinolysis in patients with non-Hodgkin's lymphomas and acute leukemias. Eur. J. Haematol 47 (1991) 55 - 59
68. Zurborn K-H: Hemostasis and hormonal tumor therapy: epidemiology and clinical studies. Gynecol Endocrinol; 7 (Suppl.) (1993) 1 - 5